Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

AbbVie’s upadacitinib tops Humira again in arthritis trial

Firm says pipeline drug only JAK inhibitor to show superiority

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class

- PMLiVE

Sobi takes ownership of rare disease drug Gamifant for $518m

Fulfils rare disease firm's global expansion plans

- PMLiVE

£1 billion cuts to public health must be reversed, say charities

Cuts already having impact

- PMLiVE

EMD Serono allies with ‘free sequencing’ firm Nebula

Free genomic sequencing in exchange for data use

- PMLiVE

Type 1 diabetes prevention promise sends Provention Bio soaring

Remarkable results prompt firm to consider regulatory pathway

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

Novo looking to challenge with oral semaglutide

- PMLiVE

J&J takes option on Genmab follow-up to Darzalex

Blockbuster partners look to next chapter - while takeover talk persists

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links